Related Experiment Video
Updated: Feb 18, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Hepatitis C Virus Clearance in Older Adults
Antonio Massimo Ippolito1, Angelo Iacobellis1, Michele Milella2
1Division of Gastroenterology, Casa Sollievo Sofferenza Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo, Italy.
Older adults (80+) with Hepatitis C Virus (HCV) infection achieved high sustained viral response (SVR) rates using direct-acting antiviral (DAA) therapy. DAAs are safe and effective, with specific patient factors predicting better outcomes.
Area of Science:
- Hepatology
- Geriatric Medicine
- Infectious Diseases
Background:
- Chronic Hepatitis C Virus (HCV) infection poses significant health risks, particularly in older adult populations.
- Direct-acting antiviral (DAA) therapies have revolutionized HCV treatment, but data on very elderly individuals are limited.
- Assessing treatment efficacy and safety in adults aged 80 and above is crucial for optimizing care.
Purpose of the Study:
- To evaluate the sustained viral response (SVR) rates in individuals aged 80 and older treated with direct-acting antiviral (DAA) therapy for Hepatitis C Virus (HCV).
- To assess the safety and global clinical effect of various DAA combinations in this elderly cohort.
- To identify risk factors for adverse events in older adults undergoing DAA treatment for HCV.
Main Methods:
- A cohort of 253 participants aged 80 and older with chronic HCV infection (213 with cirrhosis, 40 with advanced fibrosis) was studied.
- Treatment efficacy and safety were investigated using different DAA combinations.
- Participants were staged using Child-Pugh-Turcotte, MELD, and D'Amico systems; comorbidities and clinical events were meticulously recorded.
Main Results:
- Ninety-five percent of participants achieved SVR, irrespective of sex, HCV genotype, or treatment schedule.
- During a mean follow-up of 14 months, 34 events occurred in 27 participants, including hepatocellular carcinoma, hepatic decompensation, nonhepatic events, and deaths.
- Multivariate analysis identified D'Amico Stages 4-5, low baseline serum albumin (<3.5 mg/dL), and ≥3 comorbidities as risk factors for adverse events.
Conclusions:
- Direct-acting antiviral (DAA) therapy is safe and effective for older adults (80+) with HCV-related advanced fibrosis or cirrhosis in a real-world setting.
- Patients with preserved albumin synthesis and fewer than three baseline comorbidities are most likely to benefit from DAA therapy.
- These findings support the use of DAAs in the elderly population, with careful consideration of individual risk factors.
Related Concept Videos
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Retrovirus Life Cycles
Hepatic Drug Clearance: Role of Transporters
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...

